ClassID:

109186

C12N2310/341 - page 3 - CPC Classification

Classification description:

Structure or type of the nucleic acid; Chemical structure; Spatial arrangement of the modifications Gapmers, i.e. of the type ===---===

Recent Application in this class:
#601
20170335322
2017-11-23

Compounds and methods for the modulation of COMP

#602
20170327824
2017-11-16

SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF

#603
20170327823
2017-11-16

Selective Reactivation of Genes on the Inactive X Chromosome

#604
20170321216
2017-11-09

Modulation of AGPAT5 expression

#605
20170319614
2017-11-09

Antisense-oligonucleotides as inhibitors of TGF-R signaling

#606
20170314026
2017-11-02

Modulation of prekallikrein (PKK) expression

#607
20170314025
2017-11-02

Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease

#608
20170306331
2017-10-26

Anti-TNF compounds

#609
20170298349
2017-10-19

Intergenic RNAS and methods for modulating gene expression and pathogenesis in

#610
20170283804
2017-10-05

ANTISENSE COMPOUNDS AND USES THEREOF

#611
20170275628
2017-09-28

Antisense design

#612
20170275627
2017-09-28

Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent

#613
20170275620
2017-09-28

MODULATION OF APOLIPOPROTEIN C-III EXPRESSION

#614
20170268004
2017-09-21

MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION

#615
20170268002
2017-09-21

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#616
20170253877
2017-09-07

Allele-specific therapy for huntington disease haplotypes

#617
20170240892
2017-08-24

Polynucleotide agents targeting Serpinc1 (AT3) and methods of use thereof

#618
20170233732
2017-08-17

MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS

#619
20170211071
2017-07-27

Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF

#620
20170211065
2017-07-27

Multimetric oligonucleotide compounds

#621
20170204418
2017-07-20

Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof

#622
20170198288
2017-07-13

Targeting human satellite II (HSATII)

#623
20170191064
2017-07-06

Oligonucleotides for inducing paternal UBE3A expression

#624
20170183661
2017-06-29

Compositions and methods for modulating PKK expression

#625
20170183659
2017-06-29

Polynucleotide agents targeting complement component C5 and methods of use thereof

#626
20170182082
2017-06-29

Antisense compounds

#627
20170175116
2017-06-22

Compositions and methods for decreasing tau expression

#628
20170175114
2017-06-22

Compositions for modulating Ataxin 2 expression

#629
20170175113
2017-06-22

Methods for modulating Ataxin 2 expression

#630
20170159056
2017-06-08

ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF

#631
20170159055
2017-06-08

Compositions and methods for modulating complement factor B expression

#632
20170145424
2017-05-25

COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS

#633
20170145413
2017-05-25

Cancer treatment

#634
20170145409
2017-05-25

Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom

#635
20170137814
2017-05-18

Organic compositions to treat APOC3-related diseases

#636
20170136055
2017-05-18

Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof

#637
20170130224
2017-05-11

LINKAGE MODIFIED GAPPED OLIGOMERIC COMPOUNDS AND USES THEREOF

#638
20170121710
2017-05-04

Methods and compositions for modulating apolipoprotein (a) expression

#639
20170096668
2017-04-06

Compounds and methods for enhanced cellular uptake

#640
20170073689
2017-03-16

MODULATORS OF GROWTH HORMONE RECEPTOR

#641
20170073688
2017-03-16

Modulation of TMPRSS6 expression

#642
20170044539
2017-02-16

Oligomeric compounds comprising alpha-beta-constrained nucleic acid

#643
20170044526
2017-02-16

Linkage modified oligomeric compounds

#644
20170037410
2017-02-09

Compositions for modulating SOD-1 expression

#645
20170037402
2017-02-09

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#646
20170035798
2017-02-09

MODULATION OF FACTOR 11 EXPRESSION

#647
20170029815
2017-02-02

RNAi agents modified at the 4′-C position

#648
20170022501
2017-01-26

METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)

#649
20170016002
2017-01-19

Method of Treating Cancer by Inhibition of DNA Repair Proteins

#650
20170015997
2017-01-19

Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer

#651
20170009229
2017-01-12

Inhibition of NEAT1 for treatment of solid tumors

#652
20170002359
2017-01-05

Modulation of prekallikrein (PKK) expression

#653
20160369275
2016-12-22

Modulation of transthyretin expression

#654
20160369273
2016-12-22

Compositions and their uses directed to huntingtin

#655
20160362688
2016-12-15

COMPOSITIONS AND METHODS OF USING MICRORNA INHIBITORS

#656
20160362687
2016-12-15

Methods and compositions for modulating alpha-1 antitrypsin expression

#657
20160355819
2016-12-08

Potent LNA oligonucleotides for the inhibition of HIF-1A expression

#658
20160348111
2016-12-01

Antisense design

#659
20160348105
2016-12-01

Compounds of chemically modified oligonucleotides and methods of use thereof

#660
20160348104
2016-12-01

Modulation of signal transducer and activator of transcription 3 (STAT3) expression

#661
20160348100
2016-12-01

MODULATION OF TRANSTHYRETIN EXPRESSION

#662
20160312217
2016-10-27

Modulation of huntingtin expression

#663
20160304871
2016-10-20

Compositions for modulating C9ORF72 expression

#664
20160244768
2016-08-25

Method for reducing circulating leukocytes in a human subject

#665
20160244766
2016-08-25

Compositions and methods for inhibiting expression of the ALAS1 gene

#666
20160244757
2016-08-25

Compositions and methods for modulating neuronal excitability and motor behavior

#667
20160244756
2016-08-25

Formats for organic compounds for use in RNA interference

#668
20160237434
2016-08-18

Modulation of apolipoprotein C-III expression

#669
20160237432
2016-08-18

METHODS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT

#670
20160237427
2016-08-18

Tau antisense oligomers and uses thereof

#671
20160235856
2016-08-18

Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types

#672
20160230172
2016-08-11

COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT

#673
20160208259
2016-07-21

Targeting microRNAs for metabolic disorders

#674
20160201063
2016-07-14

EPIGENETIC REGULATORS OF FRATAXIN

#675
20160194638
2016-07-07

Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals

#676
20160194637
2016-07-07

Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals

#677
20160194349
2016-07-07

Compositions and methods for modulating angiopoietin-like 3 expression

#678
20160186173
2016-06-30

C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders

#679
20160160217
2016-06-09

COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING MUSCULAR DYSTROPHY

#680
20160152974
2016-06-02

Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile

#681
20160145620
2016-05-26

Oligomers with improved off-target profile

#682
20160145617
2016-05-26

Compositions for modulating Tau expression

#683
20160145614
2016-05-26

Double-stranded agents for delivering therapeutic oligonucleotides

#684
20160138029
2016-05-19

Antisense-oligonucleotides as inhibitors of TGF-R signaling

#685
20160138025
2016-05-19

Oligonucleotide conjugates

#686
20160138014
2016-05-19

ANTISENSE COMPOUNDS AND USES THEREOF

#687
20160130583
2016-05-12

Double-stranded antisense nucleic acid with exon-skipping effect

#688
20160130582
2016-05-12

OLIGONUCLEOTIDE MODULATORS OF B-CELL CLL/LYMPHOMA 11A (BCL11A) AND USES THEREOF

#689
20160108396
2016-04-21

OLIGOMERS TARGETING HEXANUCLEOTIDE REPEAT EXPANSION IN HUMAN C9ORF72 GENE

#690
20160090598
2016-03-31

Antisense compounds and uses thereof

#691
20160090596
2016-03-31

Compositions and methods for modulating apolipoprotein (a) expression

#692
20160090595
2016-03-31

Compositions and methods for modulating apolipoprotein C-III expression

#693
20160076037
2016-03-17

Modified TGF-beta oligonucleotides

#694
20160076032
2016-03-17

Compositions and methods

#695
20160076031
2016-03-17

Phosphorous-linked oligomeric compounds and their use in gene modulation

#696
20160076030
2016-03-17

Compositions and methods for modulating HBV expression

#697
20160068846
2016-03-10

Modulation of androgen receptor expression

#698
20160068845
2016-03-10

Modulation of dystrophia myotonica-protein kinase (DMPK) expression

#699
20160060632
2016-03-03

Modified TGF-beta2 oligonucleotides

#700
20160060626
2016-03-03

MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION

#701
20160060625
2016-03-03

MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION

#702
20160053256
2016-02-25

COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN

#703
20160046945
2016-02-18

Modulation of hepatitis B virus (HBV) expression

#704
20160040170
2016-02-11

Long interfering nucleic acid duplexes targeting multiple RNA targets

#705
20160040167
2016-02-11

Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease

#706
20160032286
2016-02-04

Inhibitors of MYH7B and uses thereof

#707
20160024496
2016-01-28

Methods for monitoring C9ORF72 expression

#708
20160024495
2016-01-28

LNA antisense oligonucleotides for the modulation of Myc expression

#709
20160017329
2016-01-21

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#710
20160002625
2016-01-07

Cancer treatment

#711
20150376625
2015-12-31

Selective antisense compounds and uses thereof

#712
20150376623
2015-12-31

Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

#713
20150376614
2015-12-31

Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations

#714
20150376612
2015-12-31

CCCTC-Binding Factor (CTCF) RNA Interactome

#715
20150368642
2015-12-24

LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES

#716
20150344879
2015-12-03

Compounds and methods for modulating gene expression

#717
20150337304
2015-11-26

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#718
20150322436
2015-11-12

Oligomeric compounds and compositions for the use in modulation of micrornas

#719
20150322429
2015-11-12

SNPs OF APOLIPOPROTEIN B AND MODULATION OF THEIR EXPRESSION

#720
20150322428
2015-11-12

COMPOUNDS AND METHODS FOR IMPROVED CELLULAR UPTAKE OF ANTISENSE COMPOUNDS

#721
20150315596
2015-11-05

Antisense modulation of PTP1B expression

#722
20150315595
2015-11-05

Compositions and Methods for Modulation of ATXN3 Expression

#723
20150315588
2015-11-05

Methods of delivering multiple targeting oligonucleotides to a cell using cleavable linkers

#724
20150315587
2015-11-05

Multimeric oligonucleotides compounds having cleavable linkers

#725
20150315585
2015-11-05

Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers

#726
20150307886
2015-10-29

Compositions and methods for modulation of FGFR3 expression

#727
20150307877
2015-10-29

Compositions and their uses directed to huntingtin

#728
20150299695
2015-10-22

Multimeric oligonucleotides compounds

#729
20150297629
2015-10-22

MODULATION OF RENIN-ANGIOTENSIN SYSTEM (RAS) RELATED DISEASES BY ANGIOTENSINOGEN

#730
20150275212
2015-10-01

Oligonucleotide conjugates

#731
20150275205
2015-10-01

Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome

#732
20150267197
2015-09-24

Methods for modulating C9ORF72 expression

#733
20150267195
2015-09-24

Oligomeric compounds comprising bicyclic nucleosides and uses thereof

#734
20150259679
2015-09-17

Compositions for modulating C9ORF72 expression

#735
20150252367
2015-09-10

Modulation of transthyretin expression

#736
20150225722
2015-08-13

METHODS FOR SELECTIVE TARGETING OF HETEROCHROMATIN FORMING NON-CODING RNA

#737
20150225717
2015-08-13

Selective reactivation of genes on the inactive X chromosome

#738
20150191723
2015-07-09

Modulation of UBE3A-ATS expression

#739
20150184164
2015-07-02

ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 4 EXPRESSION

#740
20150184153
2015-07-02

Oligomeric compounds comprising bicyclic nucleotides and uses thereof

#741
20150176007
2015-06-25

Compositions and methods for modulating HBV expression

#742
20150176005
2015-06-25

Modulation of enhancer RNA mediated gene expression

#743
20150167008
2015-06-18

Antisense modulation of superoxide dismutase 1, soluble expression

#744
20150166465
2015-06-18

Lipid formulations

#745
20150159155
2015-06-11

Modulation of huntingtin expression

#746
20150141493
2015-05-21

Antisense modulation of GCCR expression

#747
20150133528
2015-05-14

Compositions and methods for modulating hemoglobin gene family expression

#748
20150099792
2015-04-09

Antisense modulation of GCGR expression

#749
20150087691
2015-03-26

Methods and compositions for modulating alpha-1-antitrypsin expression

#750
20150087599
2015-03-26

Peptide-conjugated oligonucleotide therapeutic and method of making and using same

#751
20150038550
2015-02-05

Targeting MicroRNAs for metabolic disorders

#752
20150018540
2015-01-15

Oligomer-conjugate complexes and their use

#753
20140378533
2014-12-25

MODULATION OF RNA BY REPEAT TARGETING

#754
20140371296
2014-12-18

Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression

#755
20140357701
2014-12-04

Modulation of hepatitis B virus (HBV) expression

#756
20140336370
2014-11-13

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#757
20140336237
2014-11-13

Modulation of signal transducer and activator of transcription 3 (STAT3) expression

#758
20140329882
2014-11-06

Oligomeric compounds and compositions for use in modulation of small non-coding RNAS

#759
20140323707
2014-10-30

Selective antisense compounds and uses thereof

#760
20140316121
2014-10-23

Methods and compounds useful in conditions related to repeat expansion

#761
20140314816
2014-10-23

Stabilized STAT3 decoy oligonucleotides and uses therefore

#762
20140309286
2014-10-16

Modulation of TMPRSS6 expression

#763
20140309279
2014-10-16

Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof

#764
20140302603
2014-10-09

Chimeric double-stranded nucleic acid

#765
20140301982
2014-10-09

Complement antagonists and uses thereof

#766
20140296502
2014-10-02

Antisense design

#767
20140275215
2014-09-18

Anti-clusterin monotherapy for cancer treatment

#768
20140275214
2014-09-18

Custirsen treatment with reduced toxicity

#769
20140256797
2014-09-11

Modulation of transthyretin expression

#770
20140249205
2014-09-04

Activation of quiescent stem cells

#771
20140243389
2014-08-28

Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof

#772
20140242192
2014-08-28

Clusterin antisense therapy for treatment of cancer

#773
20140235694
2014-08-21

Antisense modulation of PTP1B expression

#774
20140228300
2014-08-14

Methods for modulating factor 12 expression

#775
20140213631
2014-07-31

Methods for modulating kallikrein (KLKB1) expression

#776
20140206745
2014-07-24

Methods for modulating kallikrein (KLKB1) expression

#777
20140205633
2014-07-24

Immunostimulatory oligodeoxynucleotides

#778
20140199345
2014-07-17

Immunostimulatory oligodeoxynucleotides

#779
20140193825
2014-07-10

Modulation of angiopoietin-like 3 expression

#780
20140193457
2014-07-10

Immunostimulatory oligodeoxynucleotides

#781
20140121364
2014-05-01

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#782
20140121261
2014-05-01

C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders

#783
20140113951
2014-04-24

Method of treating cancer by inhibition of DNA repair proteins

#784
20140107330
2014-04-17

Oligomeric compounds comprising bicyclic nucleotides and uses thereof

#785
20140107184
2014-04-17

Modulation of hepatitis B virus (HBV) expression

#786
20140107180
2014-04-17

Modulation of androgen receptor expression

#787
20140100261
2014-04-10

TRPM-2 antisense therapy

#788
20140080892
2014-03-20

Antisense modulation of fibroblast growth factor receptor 4 expression

#789
20140057963
2014-02-27

Oligomeric compounds and compositions for use in modulation of small non-coding RNAS

#790
20140005252
2014-01-02

Modulation of alpha synuclein expression

#791
20130347136
2013-12-26

Compositions and methods for characterizing and treating muscular dystrophy

#792
20130331434
2013-12-12

Methods for modulating factor 12 expression

#793
20130317085
2013-11-28

Modulation of apolipoprotein C-III expression

#794
20130289092
2013-10-31

Compounds and methods for modulating interaction between proteins and target nucleic acids

#795
20130281684
2013-10-24

Compositions and their uses directed to huntingtin

#796
20130281509
2013-10-24

Antisense modulation of fibroblast growth factor receptor 4 expression

#797
20130190380
2013-07-25

Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

#798
20130189782
2013-07-25

Compositions and their uses directed to huntingtin

#799
20130165496
2013-06-27

Compounds and methods for modulating expression of DGAT2

#800
20130150425
2013-06-13

Antisense modulation of GCCR expression

#801
20130131147
2013-05-23

Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom

#802
20130116301
2013-05-09

Antisense modulation of GCGR expression

#803
20130059902
2013-03-07

METHODS AND COMPOSITIONS USEFUL IN TREATMENT OF DISEASES OR CONDITIONS RELATED TO REPEAT EXPANSION

#804
20130059777
2013-03-07

MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION

#805
20130053431
2013-02-28

Modulation of growth hormone receptor expression and insulin-like growth factor expression

#806
20130046007
2013-02-21

Selective reduction of allelic variants

#807
20130039895
2013-02-14

miR-150 for the treatment of blood disorders

#808
20130035369
2013-02-07

DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION

#809
20130035366
2013-02-07

Modulation of Hepatitis B virus (HBV) expression

#810
20130030036
2013-01-31

Modulation of forkhead box O1A expression

#811
20130028889
2013-01-31

DOSING REGIMENS FOR TREATING AND PREVENTING OCULAR DISORDERS USING C-RAF ANTISENSE

#812
20130023579
2013-01-24

Modulation of angiopoietin-like 3 expression

#813
20120322991
2012-12-20

Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types

#814
20120322850
2012-12-20

TRPM-2 antisense therapy

#815
20120316221
2012-12-13

COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA

#816
20120316219
2012-12-13

MODULATION OF APOLIPOPROTEIN(A) EXPRESSION

#817
20120295961
2012-11-22

MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION

#818
20120295958
2012-11-22

Modulation of glucagon receptor expression

#819
20120295272
2012-11-22

Proinflammatory nucleic acids

#820
20120289580
2012-11-15

Antisense modulation of PTP1B expression

#821
20120288869
2012-11-15

Modulating Gene Expression With agRNA and Gapmers Targeting Antisense Transcripts

#822
20120288536
2012-11-15

Stabilized STAT3 decoy oligonucleotides and uses therefor

#823
20120283319
2012-11-08

Method of inhibiting miR-33 using a modified oligonucleotide

#824
20120283312
2012-11-08

Modulation of eIF4E expression

#825
20120277284
2012-11-01

Modulation of signal transducer and activator of transcription 3 (STAT3)expression

#826
20120270929
2012-10-25

MODULATION OF TTC39 EXPRESSION TO INCREASE HDL

#827
20120270924
2012-10-25

Oligomeric compounds for the modulation of HIF-1A expression

#828
20120252879
2012-10-04

Modulation of huntingtin expression

#829
20120238937
2012-09-20

Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)

#830
20120232125
2012-09-13

MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 1 EXPRESSION

#831
20120214865
2012-08-23

Methods for slowing familial ALS disease progression

#832
20120214862
2012-08-23

MODULATION OF FACTOR 7 EXPRESSION

#833
20120214736
2012-08-23

COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS

#834
20120208864
2012-08-16

COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR

#835
20120202874
2012-08-09

Antisense oligonucleotide modulation of STAT3 expression

#836
20120202873
2012-08-09

RNAi probes targeting cancer-related proteins

#837
20120196921
2012-08-02

MODULATION OF SGLT-2 EXPRESSION

#838
20120183602
2012-07-19

Lipid formulation

#839
20120157514
2012-06-21

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#840
20120149893
2012-06-14

MODULATION OF EIF4E-BP2

#841
20120149755
2012-06-14

ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION

#842
20120149109
2012-06-14

MODULATION OF TRANSTHYRETIN EXPRESSION

#843
20120122959
2012-05-17

Targeting MicroRNAs for metabolic disorders

#844
20120122954
2012-05-17

Antisense oligomers targeting PCSK9

#845
20120122216
2012-05-17

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#846
20120115932
2012-05-10

Modulation of STAT 6 expression

#847
20120115930
2012-05-10

COMPOSITIONS AND THEIR USES DIRECTED TO HEPCIDIN

#848
20120115928
2012-05-10

MIRNA AND ITS TARGETS RESPECTIVELY THE PROTEINS MADE BASED ON THE TARGETS AS A PROGNOSTIC, DIAGNOSTIC BIOMARKER AND THERAPEUTIC AGENT FOR CANCER

#849
20120115926
2012-05-10

ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION

#850
20120115228
2012-05-10

Oligomeric compounds and compositions for the use in modulation of target nucleic acids

#851
20120088814
2012-04-12

METHODS OF MODULATING AN IMMUNE RESPONSE TO A VIRAL INFECTION

#852
20120083522
2012-04-05

MODULATION OF INFLAMMATORY RESPONSES BY FACTOR XI

#853
20120077866
2012-03-29

Antisense modulation of C-reactive protein expression

#854
20120077862
2012-03-29

Antisense modulation of PTP1B expression

#855
20120076781
2012-03-29

METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES

#856
20120045395
2012-02-23

MicroRNAs In Idiopathic Pulmonary Fibrosis

#857
20120035248
2012-02-09

Method for inhibiting the activity of mir-155

#858
20120029049
2012-02-02

Antisense modulation of superoxide dismutase 1, soluble expression

#859
20120022133
2012-01-26

ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION

#860
20110319471
2011-12-29

LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR

#861
20110319469
2011-12-29

SNPs of apolipoprotein B and modulation of their expression

#862
20110306652
2011-12-15

Compositions and their uses directed to huntingtin

#863
20110294868
2011-12-01

MODULATION OF TRANSTHYRETIN EXPRESSION

#864
20110230544
2011-09-22

Modulation of C-reactive protein expression

#865
20110224285
2011-09-15

Oligomeric compounds for the modulation of HIF-1α expression

#866
20110224281
2011-09-15

RNA ANTAGONISTS TARGETING HSP70-2

#867
20110224277
2011-09-15

Oligomeric compounds and compositions for use in modulation of small non-coding RNAS

#868
20110213136
2011-09-01

ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION

#869
20110207797
2011-08-25

ENHANCED ANTISENSE OLIGONUCLEOTIDES

#870
20110190370
2011-08-04

Modulation of HIF1α and HIF2α expression

#871
20110183931
2011-07-28

Potent LNA oligonucleotides for the inhibition of HIF-1A expression

#872
20110177097
2011-07-21

METHODS FOR MODULATING EXPRESSION OF CREB

#873
20110172296
2011-07-14

MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 1 EXPRESSION

#874
20110171730
2011-07-14

Conjugates For Use In Hepatocyte Free Uptake Assays

#875
20110171176
2011-07-14

Complement antagonists and uses thereof

#876
20110166065
2011-07-07

Modulation of glucose-6-phosphatase translocase expression

#877
20110160283
2011-06-30

Modulation of CD40 expression

#878
20110152354
2011-06-23

Bispecific oligonucleotide for the treatment of CNS malignancies

#879
20110152351
2011-06-23

Modulation of SMRT expression

#880
20110152348
2011-06-23

Methods for treating androgen receptor dependent disorders including cancers

#881
20110144185
2011-06-16

RNA antagonists targeting Hsp27

#882
20110136889
2011-06-09

Compositions and their uses directed to acetyl-CoA carboxylases

#883
20110124715
2011-05-26

Antiviral Oligonucleotides Having a Conserved G4 Core Sequence

#884
20110124709
2011-05-26

RNA ANTAGONISTS TARGETING GLI2

#885
20110123998
2011-05-26

Materials and Methods for Treatment of Cancer

#886
20110123521
2011-05-26

Methods for modulating expression of RBP4

#887
20110117646
2011-05-19

Antisense modulation of C-reactive protein expression

#888
20110112171
2011-05-12

Compositions and their uses directed to PTPRU

#889
20110112170
2011-05-12

Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity

#890
20110105586
2011-05-05

Compositions and their uses directed to gemin genes

#891
20110098340
2011-04-28

ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION

#892
20110092573
2011-04-21

Modification of MYD88 splicing using modified oligonucleotides

#893
20110077285
2011-03-31

RNA antagonist compounds for the modulation of PIK3CA expression

#894
20110065775
2011-03-17

Compounds and methods for modulating expression of SGLT2

#895
20110060030
2011-03-10

Modulation of apolipoprotein C-III expression

#896
20110059895
2011-03-10

MODULATION OF FACTOR 9 EXPRESSION

#897
20110054011
2011-03-03

RNA Antagonist Compounds for the Modulation of FABP4/AP2

#898
20110054004
2011-03-03

Method for reducing scarring during wound healing using antisense compounds directed to CTGF

#899
20110054003
2011-03-03

Antisense oligonucleotide modulation of STAT3 expression

#900
20110046206
2011-02-24

DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION